Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
|ClinicalTrials.gov Identifier: NCT01760499|
Recruitment Status : Completed
First Posted : January 4, 2013
Last Update Posted : April 19, 2017
|Condition or disease||Intervention/treatment||Phase|
|Melanoma||Drug: PV-10 Procedure: Surgery||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study|
|Study Start Date :||January 24, 2013|
|Primary Completion Date :||December 29, 2015|
|Study Completion Date :||April 2017|
Experimental: Immunotherapy Followed by Surgery
PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
Other Name: 10% rose bengal disodiumProcedure: Surgery
Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
- Occurrence of Change in Infiltration of Immune Cells [ Time Frame: At baseline and 7-14 days after PV-10 treatment ]The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. Tumor core needle biopsies will be collected from the designated injected and uninjected lesions one week prior to intralesional PV-10 therapy. Biopsy samples will be fixed in formalin and embedded in paraffin for immunohistochemical (IHC) staining. On day 0, the injected lesion will be treated with up to 5 mL of PV-10. Seven to 14 days after intralesional PV-10 treatment, the injected and uninjected lesions will be resected. A portion of each tumor equivalent to a core needle biopsy specimen will be fixed in formalin and embedded in paraffin for IHC staining. Immune cell infiltration will be compared between untreated baseline lesions and post-treatment lesions (injected or uninjected) by a blinded pathologist at Moffitt Cancer Center. Measurement is the ordinal level of the T-cell infiltration into tumors with three levels: 0, no brisk, and brisk.
- Frequency and Phenotype of Circulating Immune Cells in Peripheral Blood Mononuclear Cells (PBMC) [ Time Frame: At baseline, 7-14 days after treatment and 21-28 days after treatment ]This secondary endpoint is to enumerate and phenotype patient immune cells in peripheral blood before and after intralesional (IL) PV-10 treatment. The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. T cells will be enumerated and phenotyped in patient blood one week prior to and 7-14 days after intralesional PV-10 therapy. An additional blood draw 14 days post surgery will take place at the end of the study at the time of the surgical follow-up/end of study visit. These samples will be used for in vitro experiments in order to determine the frequency and phenotype of T cells in the blood by flow cytometry.
- Titer of Anti-tumor IgG in the Serum [ Time Frame: At baseline, 7-14 days after treatment and 21-28 days after treatment ]This secondary endpoint is to enumerate anti-tumor immunoglobulin G (IgG) in peripheral blood before and after IL PV-10 treatment. Titer of anti-tumor IgG in the serum prior to, 7-14 days after, and 21-28 days after PV-10 treatment. The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. Serum will be phenotyped from patients one week prior to, 7-14 days after and 21-28 days after IL PV-10 therapy. Serum will be isolated from peripheral blood by centrifugation and will be used to stain patient tumor samples obtained from surgical resection. Bound serum antibodies will be detected by staining with antihuman IgG antibodies and detected by flow cytometry.
- Occurrence of Adverse Events (AEs) [ Time Frame: During PV-10 administration visit, after 7-14 days, at study end (day 28 or early termination) ]Local and systemic toxicity signs and symptoms per the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Any adverse experiences associated with participation on the trial will be recorded. Adverse events will be assessed within 30 minutes following PV-10 administration and 4 hours after PV-10 administration. Adverse events assessment: Questions about how participants have been feeling and any changes in the way participants feel immediately after the study drug was given and 4 hours later.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01760499
|United States, Florida|
|H. Lee Moffitt Cancer Center and Research Institute|
|Tampa, Florida, United States, 33612|
|Principal Investigator:||Amod A. Sarnaik, M.D.||H. Lee Moffitt Cancer Center and Research Institute|